An investigation of a large performance improvement clinical database revealed that most individuals receiving CAR-T have diagnoses of ALL or large B-cell lymphoma.
For children with relapsed or refractory B-cell acute lymphoblastic leukemia, tisagenlecleucel was deemed cost-effective, yet long-term outcomes are still uncertain.
Survivorship plans for adolescent and young adult survivors need to consider the relative long-term survival for AYAs with certain cancers. Those with certain cancers may have excess long-term mortality.
Consolidation with ATO allows a decrease in the cumulative dose of anthracycline while maintaining survival rates and a low risk of relapse among pediatric patients with APL.
The NCI and COG announced open enrollment for a study designed to evaluate the effectiveness of genetically matched targeted therapies for pediatric patients with cancer.
Pediatric patients with hematological malignancies who receive HSCT from an unrelated donor have greater benefit from a 15 mg/kg vs a 30 mg/kg dose of ATLG.
According to this study’s authors, subsequent meningiomas among pediatric cancer survivors lead to increased mortality and a high rate of neurologic sequelae.
Researchers have constructed baseline event-free survival outcomes as a comparison for future trials, so that time to disease progression can be used as an end point.
